Cargando…

Prefibrotic myelofibrosis: treatment algorithm 2018

Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture is heterogeneous, ranging from isolated thrombocytosis, mimicking essential thrombocythemia (ET), to symptoms of high-ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Finazzi, Guido, Vannucchi, Alessandro M., Barbui, Tiziano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221891/
https://www.ncbi.nlm.nih.gov/pubmed/30405096
http://dx.doi.org/10.1038/s41408-018-0142-z
_version_ 1783369102662828032
author Finazzi, Guido
Vannucchi, Alessandro M.
Barbui, Tiziano
author_facet Finazzi, Guido
Vannucchi, Alessandro M.
Barbui, Tiziano
author_sort Finazzi, Guido
collection PubMed
description Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture is heterogeneous, ranging from isolated thrombocytosis, mimicking essential thrombocythemia (ET), to symptoms of high-risk PMF. Retrospective studies showed that survival of patients with pre-PMF is worse than that of ET and better than overt PMF. Whilst a specific prognostic score is lacking, the International Prognostic Scoring System is able to predict survival in pre-PMF patients, yet failing to separate intermediate-1 and -2 groups, and can be used in clinical practice. Each patient should be evaluated for, and interventions adapted to, both life-expectancy and the risk of bleeding and thrombosis. In low-risk patients with expected long survival, observation only is recommended; in cumulated intermediate-1 and -2 risk cases, whose median survival is projected at more than 10 years, treatment is based on symptoms; in high risk cases, with median survival lower than 5 years, intensive management is required. A pragmatic approach to address the risk of bleeding and thrombosis includes: no treatment or low-dose aspirin in asymptomatic patients; aspirin or oral anticoagulation if previous arterial or venous thrombosis, and hydroxyurea as first-line cytoreduction in case of thrombocytosis or leukocytosis.
format Online
Article
Text
id pubmed-6221891
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62218912018-11-08 Prefibrotic myelofibrosis: treatment algorithm 2018 Finazzi, Guido Vannucchi, Alessandro M. Barbui, Tiziano Blood Cancer J Current Treatment Algorithm Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture is heterogeneous, ranging from isolated thrombocytosis, mimicking essential thrombocythemia (ET), to symptoms of high-risk PMF. Retrospective studies showed that survival of patients with pre-PMF is worse than that of ET and better than overt PMF. Whilst a specific prognostic score is lacking, the International Prognostic Scoring System is able to predict survival in pre-PMF patients, yet failing to separate intermediate-1 and -2 groups, and can be used in clinical practice. Each patient should be evaluated for, and interventions adapted to, both life-expectancy and the risk of bleeding and thrombosis. In low-risk patients with expected long survival, observation only is recommended; in cumulated intermediate-1 and -2 risk cases, whose median survival is projected at more than 10 years, treatment is based on symptoms; in high risk cases, with median survival lower than 5 years, intensive management is required. A pragmatic approach to address the risk of bleeding and thrombosis includes: no treatment or low-dose aspirin in asymptomatic patients; aspirin or oral anticoagulation if previous arterial or venous thrombosis, and hydroxyurea as first-line cytoreduction in case of thrombocytosis or leukocytosis. Nature Publishing Group UK 2018-11-07 /pmc/articles/PMC6221891/ /pubmed/30405096 http://dx.doi.org/10.1038/s41408-018-0142-z Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Current Treatment Algorithm
Finazzi, Guido
Vannucchi, Alessandro M.
Barbui, Tiziano
Prefibrotic myelofibrosis: treatment algorithm 2018
title Prefibrotic myelofibrosis: treatment algorithm 2018
title_full Prefibrotic myelofibrosis: treatment algorithm 2018
title_fullStr Prefibrotic myelofibrosis: treatment algorithm 2018
title_full_unstemmed Prefibrotic myelofibrosis: treatment algorithm 2018
title_short Prefibrotic myelofibrosis: treatment algorithm 2018
title_sort prefibrotic myelofibrosis: treatment algorithm 2018
topic Current Treatment Algorithm
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221891/
https://www.ncbi.nlm.nih.gov/pubmed/30405096
http://dx.doi.org/10.1038/s41408-018-0142-z
work_keys_str_mv AT finazziguido prefibroticmyelofibrosistreatmentalgorithm2018
AT vannucchialessandrom prefibroticmyelofibrosistreatmentalgorithm2018
AT barbuitiziano prefibroticmyelofibrosistreatmentalgorithm2018